Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Commentary: Il-12-Secreting Tumor-Targeted Chimeric Antigen Receptor T Cells: An Unaddressed Concern on Koneru Et Al. (2015) Publisher



Mirzaei HR1 ; Hadjati J1
Authors

Source: OncoImmunology Published:2016


Abstract

abstract: To date, chimeric antigen receptor (CAR) T cells have shown remarkable responses in patients with certain hematological malignancies particularly acute lymphocytic leukemia (ALL), but have led to more limited success with solid tumors probably due to immunosuppressive networks in the tumor environment. To overcome this issue, Koneru et al. have recently demonstrated IL-12-producing CAR T cells, also known as armored CAR T cells, to simultaneously target both ovarian tumor cells and their microenvironment. This commentary challenges the study design of Koneru et al. study and highlights the importance of choosing the most appropriate experimental animal model in preclinical cancer studies. © 2016, © Taylor & Francis Group, LLC.
Other Related Docs
5. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
8. Tumor Immunology, Clinical Immunology (2022)
13. Characterization of a Xenograft Model for Anti-Cd19 Car T Cell Studies, Clinical and Translational Oncology (2021)
17. Generation of Cd19-Targeted Chimeric Antigen Receptor T Cells, Archives of Iranian Medicine (2019)